FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025889791> ?p ?o ?g. }

• W3025889791 endingPage "3404" @default.
• W3025889791 startingPage "3393" @default.
• W3025889791 abstract "The efficacy of several antimicrobial agents has been hindered due to the increasing frequency of multidrug-resistant (MDR) Pseudomonas aeruginosa strains. So, the need for new antibacterial drugs or drug combinations is urgent. Recently, desirable antibacterial effects were reported for many metals nanoparticles such as TiO2 nanoparticles (TDNs).This study aims to investigate the prevalence of MDR P. aeruginosa and assess the efficiency of TDN in the treatment of MDR P. aeruginosa-associated infections.The synthesis of TDN by the sol-gel method was carried out. Particle size measurements and morphology were done using dynamic light scattering (DLS) and high-resolution transmission electron microscopy (HR-TEM). To investigate the physical and chemical changes of drugs due to the combination, the tested drugs, both alone and in combination with TDN, were subjected to differential scanning calorimetry (DSC), infrared (IR) spectroscopy, and X-ray diffraction studies. Antimicrobial susceptibility was detected by agar disc-diffusion assay. The minimum inhibitory concentration (MIC) of TDN and the tested antibiotics were assessed by the agar dilution method. Checkerboard analysis was performed to determine the combined effect of TDN and the tested antibiotics against 25 MDR P. aeruginosa strains.TDNs were prepared with an average particle size of 64.77 ± 0.14 nm with an accepted polydispersity index (PDI) value of 0.274 ± 0.004. TEM showed that the particles were shaped into irregular spheres. Twenty-five P. aeruginosa isolates that were absolutely resistant to cefepime (100%), highly resistant to ceftriaxone (96%), amikacin (80%), and ciprofloxacin (76%) were selected. Superior antibacterial activity of TDN was observed against the selected 25 MDR P. aeruginosa isolates. The combination of TDN and cefepime were found to show synergistic activity against all tested isolates followed by ceftriaxone (96%), amikacin (88%), and ciprofloxacin (80%).Using TDN in combination with antibiotics can help in the treatment of MDR P. aeruginosa-associated infections. So, preparation of topical pharmaceutical dosage forms containing a combination of these antibiotics and TDN can be useful against MDR P. aeruginosa." @default.
• W3025889791 created "2020-05-21" @default.
• W3025889791 creator A5000485366 @default.
• W3025889791 creator A5018038953 @default.
• W3025889791 creator A5042240256 @default.
• W3025889791 creator A5052089826 @default.
• W3025889791 date "2020-05-01" @default.
• W3025889791 modified "2023-10-16" @default.
• W3025889791 title "<p>Comparative Study of Antibacterial Effects of Titanium Dioxide Nanoparticles Alone and in Combination with Antibiotics on MDR <em>Pseudomonas aeruginosa</em> Strains</p>" @default.
• W3025889791 cites W1973879738 @default.
• W3025889791 cites W1976303009 @default.
• W3025889791 cites W1999862259 @default.
• W3025889791 cites W2001934072 @default.
• W3025889791 cites W2009791213 @default.
• W3025889791 cites W2016562927 @default.
• W3025889791 cites W2028804839 @default.
• W3025889791 cites W2041633842 @default.
• W3025889791 cites W2043721389 @default.
• W3025889791 cites W2055490249 @default.
• W3025889791 cites W2056917379 @default.
• W3025889791 cites W2059900328 @default.
• W3025889791 cites W2091277864 @default.
• W3025889791 cites W2133152249 @default.
• W3025889791 cites W2142025754 @default.
• W3025889791 cites W2167015616 @default.
• W3025889791 cites W2173144055 @default.
• W3025889791 cites W2322494889 @default.
• W3025889791 cites W2323662504 @default.
• W3025889791 cites W2333162163 @default.
• W3025889791 cites W2407774107 @default.
• W3025889791 cites W2479544098 @default.
• W3025889791 cites W2609328338 @default.
• W3025889791 cites W2766007387 @default.
• W3025889791 cites W2803312567 @default.
• W3025889791 cites W2804846127 @default.
• W3025889791 cites W2810498368 @default.
• W3025889791 cites W2838038643 @default.
• W3025889791 cites W2897418793 @default.
• W3025889791 cites W2903381708 @default.
• W3025889791 cites W2903416497 @default.
• W3025889791 cites W2915489445 @default.
• W3025889791 cites W2945103426 @default.
• W3025889791 cites W2972813069 @default.
• W3025889791 cites W2982147600 @default.
• W3025889791 cites W2990762497 @default.
• W3025889791 cites W2993701708 @default.
• W3025889791 cites W3016335704 @default.
• W3025889791 cites W3213929325 @default.
• W3025889791 cites W4241532263 @default.
• W3025889791 cites W4251033447 @default.
• W3025889791 doi "https://doi.org/10.2147/ijn.s246310" @default.
• W3025889791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7236244" @default.
• W3025889791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32523339" @default.
• W3025889791 hasPublicationYear "2020" @default.
• W3025889791 type Work @default.
• W3025889791 sameAs 3025889791 @default.
• W3025889791 citedByCount "27" @default.
• W3025889791 countsByYear W30258897912020 @default.
• W3025889791 countsByYear W30258897912021 @default.
• W3025889791 countsByYear W30258897912022 @default.
• W3025889791 countsByYear W30258897912023 @default.
• W3025889791 crossrefType "journal-article" @default.
• W3025889791 hasAuthorship W3025889791A5000485366 @default.
• W3025889791 hasAuthorship W3025889791A5018038953 @default.
• W3025889791 hasAuthorship W3025889791A5042240256 @default.
• W3025889791 hasAuthorship W3025889791A5052089826 @default.
• W3025889791 hasBestOaLocation W30258897911 @default.
• W3025889791 hasConcept C121332964 @default.
• W3025889791 hasConcept C13965031 @default.
• W3025889791 hasConcept C176947019 @default.
• W3025889791 hasConcept C185592680 @default.
• W3025889791 hasConcept C192562407 @default.
• W3025889791 hasConcept C2777427914 @default.
• W3025889791 hasConcept C2777637488 @default.
• W3025889791 hasConcept C2780104969 @default.
• W3025889791 hasConcept C2780493024 @default.
• W3025889791 hasConcept C39519442 @default.
• W3025889791 hasConcept C4937899 @default.
• W3025889791 hasConcept C501593827 @default.
• W3025889791 hasConcept C523546767 @default.
• W3025889791 hasConcept C54355233 @default.
• W3025889791 hasConcept C86803240 @default.
• W3025889791 hasConcept C89423630 @default.
• W3025889791 hasConcept C97355855 @default.
• W3025889791 hasConceptScore W3025889791C121332964 @default.
• W3025889791 hasConceptScore W3025889791C13965031 @default.
• W3025889791 hasConceptScore W3025889791C176947019 @default.
• W3025889791 hasConceptScore W3025889791C185592680 @default.
• W3025889791 hasConceptScore W3025889791C192562407 @default.
• W3025889791 hasConceptScore W3025889791C2777427914 @default.
• W3025889791 hasConceptScore W3025889791C2777637488 @default.
• W3025889791 hasConceptScore W3025889791C2780104969 @default.
• W3025889791 hasConceptScore W3025889791C2780493024 @default.
• W3025889791 hasConceptScore W3025889791C39519442 @default.
• W3025889791 hasConceptScore W3025889791C4937899 @default.
• W3025889791 hasConceptScore W3025889791C501593827 @default.
• W3025889791 hasConceptScore W3025889791C523546767 @default.
• W3025889791 hasConceptScore W3025889791C54355233 @default.

• next